Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29726896 | 1.00 | CACNA2D1 (0.51) | CACNA2D1TOP2AFLT3PARP1TP53 | |
| SCHEMBL18947845 | 0.86 | NCF1 (0.57) | TOP2AFLT3POLBNPC1GAA | |
| SCHEMBL28227432 | 0.84 | CACNA2D1 (0.51) | CACNA2D1TOP2AFLT3PARP1TP53 | |
| SCHEMBL16008904 | 0.83 | CACNA2D1 (0.50) | CACNA2D1TOP2AFLT3PARP1TP53 | |
| SCHEMBL8696930 | 0.77 | TP53 (0.60) | CACNA2D1TOP2AFLT3TP53POLB | |
| SCHEMBL19594008 | 0.76 | KDM4E (0.45) | TOP2AMAPTRXFP1GAA | |
| Hydrochloric Acid SCHEMBL8693301 | 0.75 | TP53 (0.58) | CACNA2D1TOP2AFLT3TP53POLB | |
| Hydrochloric Acid SCHEMBL8693296 | 0.75 | TP53 (0.58) | CACNA2D1TOP2AFLT3TP53POLB | |
| SCHEMBL11352799 | 0.74 | KDM4E (0.60) | CACNA2D1TOP2AFLT3PARP1POLB | |
| SCHEMBL28227450 | 0.74 | CACNA2D1 (0.49) | CACNA2D1TOP2AFLT3PARP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011882-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | Purdue Research Foundation (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20210198208-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-11001559-B2 | 4-substituted aminoisoquinoline derivatives | PURDUE RESEARCH FOUNDATION (US) | 2021-05-11 | — | — | US | disclosed |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190177278-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2018035072-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2018-02-22 | — | — | WO | disclosed |
| EP-2970312-B1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2970312-B1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2970312-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164596-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177278-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | CACNA2D1 3841/4885TOP2A 427/4885FLT3 3/4885 |
| US-11001559-B2 | 4-substituted aminoisoquinoline derivatives | MCL1, ABL1, FLT3 | CACNA2D1 3841/4885TOP2A 427/4885FLT3 3/4885 |
| US-20210198208-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | CACNA2D1 3841/4885TOP2A 427/4885FLT3 3/4885 |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | BRD4, BRDT, BRD3 | CACNA2D1 3237/4885TOP2A 148/4885FLT3 1901/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | CACNA2D1 3237/4885TOP2A 148/4885FLT3 1901/4885 |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | CACNA2D1 3237/4885TOP2A 148/4885FLT3 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.